Radcliffe Capital Management’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-165,205
Closed -$1.7M – 563
2023
Q2
$1.7M Hold
165,205
– – 0.14% 193
2023
Q1
$1.67M Hold
165,205
– – 0.1% 246
2022
Q4
$1.65M Hold
165,205
– – 0.05% 533
2022
Q3
$1.61M Hold
165,205
– – 0.04% 742
2022
Q2
$1.6M Buy
165,205
+19,082
+13% +$186K 0.04% 781
2022
Q1
$1.42M Buy
+146,123
New +$1.41M 0.03% 817

Radcliffe Capital Management's DALS Position: Q3 2023 in Review

Radcliffe Capital Management sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q3 2023, closing a stake of 165,205 shares — an estimated $1.7M sold.

Radcliffe Capital Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $1.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • Radcliffe Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q3 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 165,205 DA32 Life Science Tech Acquisition Corp shares in Q3 2023, an estimated $1.7M.
  • Radcliffe Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp in Q1 2022 and held it in 6 quarters.
  • Radcliffe Capital Management's DA32 Life Science Tech Acquisition Corp position peaked at $1.7M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.